| 摘要 |
It is intended to provide a drug for inhibiting estrogen-dependent diseases, prostaglandin D (PGD)-dependent gynecological diseases, immunological diseases, cancer and angiogenesis. Namely, a drug aiming at inhibiting at least one member selected from the group consisting of estrogen-dependent diseases, PGD-dependent gynecological diseases, immunological diseases, cancer and angiogenesis characterized by containing an ingredient inhibiting the activity of a histamine release factor (HRF). By inhibiting the HRF activity, the expression of genes of, for example, IL-1ß receptor, 17ß hydroxy steroid dehydrogenase (HSD), etc. is inhibited. Thus, the estrogen activity is inhibited and estrogen-dependent diseases can be prevented, treated or ameliorated thereby. As the above-described ingredient inhibiting the RHF activity, it is preferred to use artemisinin. |
